Longevity science: what did March 2026 bring?
From a database that supports thousands of aging researchers yet faces extinction, to promising experiments with plasma exchange and thyroid treatment, March 2026 delivered a wide range of developments in the search for longer, healthier lives.
Lifespan.io's monthly roundup serves as a useful thermometer for where longevity science stands right now. Not as a victory lap, but as a working checklist: what was published, what has been replicated, what is at stake. March 2026 shows a field grappling with infrastructure problems and new biological breakthroughs at the same time.
On the infrastructure side: João Pedro de Magalhães, one of the best-known figures in aging genetics, has launched a crowdfunding campaign to keep the Human Ageing Genomic Resources database alive. That database attracts more than 200,000 visitors a year and has accumulated over a thousand scientific citations, making it a basic tool for researchers around the world. The fact that such fundamental infrastructure depends on public donations says something about how fragile the funding of aging research still is, despite the surge in public interest.
Experiments worth watching
On the science side, a series of animal experiments stands out. Researchers reported progress with young plasma infusions in older animals, an approach that has been studied for some time but still lacks a clear mechanistic explanation. New results also emerged on thyroid hormone and aging, with treatment in mice showing effects on metabolic markers associated with biological age.
Also notable is the growing number of studies making use of biological clocks, measurement tools that estimate how old an organism is biologically, based on DNA methylation, independently of its calendar age. This makes comparisons between interventions more precise, but it also raises questions: biological clocks measure a correlate of aging, not aging itself. Whether an intervention that turns back the clock actually leads to better health or a longer lifespan remains an open question.
The translation problem persists
The most fundamental challenge in longevity research is unchanged: most promising results come from mice or other model organisms. Translating those findings to humans is difficult, expensive, and time-consuming. Clinical trials in the field of aging are rare, partly because "aging" is not a recognized disease and therefore has no official status as a target for drug approval.
Yet the field keeps growing. The number of publications on aging biology has multiplied several times over in the past decade. Venture capital investment in longevity companies reached record highs in 2024 and 2025. But money and publications are no guarantee of breakthroughs that actually reach people. March 2026 confirms both sides of that story.